Core Insights - Telo Genomics Corp. is advancing its minimal residual disease (MRD) biomarker assay technologies in multiple myeloma patients as part of the TELO-DMRD clinical validation study [1][2] Group 1: Company Overview - Telo Genomics Corp. is a biotech company focused on developing a leading telomere technology platform with applications in oncology, particularly in measuring genomic instability [1][7] - The company is pioneering liquid biopsy technologies, which are less invasive and more easily replicated than traditional diagnostic methods [7] Group 2: Clinical Trials and Studies - The TELO-DMRD clinical trial, conducted in collaboration with McGill University, aims to evaluate the sensitivity of Telo's MRD assays using Adaptive Biotechnologies' clonoSEQ assay technology [2][4] - The study plans to include up to ten patients, with the potential for expansion based on initial results, and the first patient samples have already been analyzed [3][4] Group 3: Objectives and Applications - The clinical trials have two main objectives: to identify and quantify MRD cells in patients' blood post-marrow transplantation and to profile these cells to assess disease aggressiveness using Telo's proprietary technology [4] - The MRD tests are designed to be liquid biopsy-based, aligning with the trend towards precision medicine in oncology [4] Group 4: Market Potential - The global MRD testing market is projected to reach USD 4.1 billion by 2032, indicating substantial growth potential in the industry [6]
Telo Genomics Assessing MRD Status in TELO-DMRD Study